It is very difficult time for bio-sectors now, even though the same sector has once attracted so much attention and a bundle of investment money.
If you look back on history, there have been ups and downs in every field, but in the end, they have made macroscopic upward-rightward progress.

iYoung aims to achieve fundamental treatment without insulin injection by differentiating pluripotent stem cells such as embryonic stem cells and induced pluripotent stem cells outside of the body and transplanting these stem cell-derived pancreatic cells into diabetic patients.

We are also developing a first-in-class chemical drug for metabolic dysfunction-associated steatohepatitis (MASH), which is rapidly increasing in prevalence worldwide. We have developed a new drug candidate (STK25 chemical inhibitor) in collaboration with the Korea Chemical Research Institute and are currently actively conducting preclinical tests using animals, so we hope to develop a new drug in the near future.

All members of iYoung will do our best today to treat diabetes and MASH, which are the two pillars of metabolic diseases.

Thank you.